J.Jpn. Surg. Soc.. 96(10): 671-679, 1995

---

Original article

ORAL ADMINISTRATION OF OK-432 IS AN EFFECTIVE IMMUNOTHERAPY AGAINST COLON CANCER -A STUDY IN A MURINE MESENTERIC LYMPHNODE METASTASIS MODEL-

A simple and highly reproducible mouse colonic cancer model with mesenteric lymph node (MLN) metastasis was established by injecting COLON-26 tumor cells into lymphatic nodules in the tip of vermiform appendix of BALB/C mice. In this model, antitumor effect of orally administered OK-432 was examined. OK-432 was given orally at three different periods : before injection of COLON-26 cells (Protocol-A), early after injection of COLON-26 cells (Protocol-B), and late after injection of COLON-26 cells (Protocol-C). As a result, MLN metastasis was significantly suppressed and survival rate was signficantly improved in every protocol as compared to mice without OK-432 administration. Then, in vivo anti-tumor activities of MLN cells and splenic lymphocytes were evaluated by Winn assay. Tumor neutralizing activity against syngenic COLON-26 cells was induced in the MLN cells after OK-432 administration and the effector cells were found in CD4-positive T lymphocytes because MLN cells treated with anti-L3/T4 and anti-LFA plus complement lost their anti-tumor efflcacy.
In conclusion, oral administration of OK-432 appears to be an effective immunotherapy against colonic cancer especially in the prevention and the treatment for MLN metastasis.

---

---

To read the PDF file you will need Adobe Reader installed on your computer.